NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Medical Letter on the CDC & FDA

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Drug Development



Biopharmaceutical company initiates clinical trial of TRX4 for psoriasis



September 5th, 2004

TolerRx, Inc., a biopharmaceutical company, announced the initiation of a phase 1 trial of its TRX4 monoclonal antibody in subjects with psoriasis.

This phase 1 trial will be a single-dose, dose-escalation study to establish the safety, pharmacokinetic, and pharmacodynamic profile of TRX4. Approximately thirty moderate to severe psoriasis subjects will be enrolled. The clinical trial is being conducted pursuant to an investigational new drug (IND) application filed with the U.S. Food and Drug Administration.

TRX4 is a humanized monoclonal antibody that binds to a receptor found on all mature T cells called CD3, which is involved in normal T cell...


Source: Medical Letter on the CDC & FDA (2004-09-05)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login